(Q37037518)

17 August 2017

title

Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. (English)

1 reference

17 August 2017

2

Klareskog L

1 reference

17 August 2017

van Vollenhoven RF

1

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Scandinavian Journal of Rheumatology

17 August 2017

published in

1 reference

17 August 2017

volume

36

1 reference

17 August 2017

issue

6

1 reference

17 August 2017

page(s)

418-423

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Limitations of randomized controlled clinical trials to depict accurately long-term outcomes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Empirical investigation of experimental design properties of discrete choice experiments in health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701416758

10.1080/03009740701416758

21 January 2018

Identifiers

DOI

1 reference

release_y2a67ddylzfknkzht566ao2afe

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y2a67ddylzfknkzht566ao2afe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference